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KEY PO INT S
l Loss-of-function
mutations in CD37
occur predominantly
in diffuse large B-cell
lymphoma at immune-
privileged sites.
l CD37-mutated
lymphomaB cells show
impaired CD37 cell-
surface localization,
which may have
implications for anti-
CD37 therapies.
Tetraspanin CD37 is predominantly expressed on the cell surface of mature B lymphocytes
and is currently being studied as novel therapeutic target for B-cell lymphoma. Recently,
we demonstrated that loss of CD37 induces spontaneous B-cell lymphoma in Cd37-
knockout mice and correlates with inferior survival in patients with diffuse large B-cell
lymphoma (DLBCL). Here, CD37 mutation analysis was performed in a cohort of 137
primary DLBCL samples, including 44 primary immune-privileged site-associatedDLBCL (IP-
DLBCL) samples originating in the testis or central nervous system. CD37 mutations were
exclusively identified in IP-DLBCL cases (10/44, 23%) but absent in non-IP-DLBCL cases. The
aberrations included 10 missense mutations, 1 deletion, and 3 splice-site CD37 mutations.
Modeling and functional analysis of CD37missense mutations revealed loss of function by
impaired CD37 protein expression at the plasma membrane of human lymphoma B cells.
This study provides novel insight into the molecular pathogenesis of IP-DLBCL and indicates
that anti-CD37 therapies will be more beneficial for DLBCL patients without CD37
mutations. (Blood. 2019;134(12):946-950)
Introduction
Diffuse large B-cell lymphoma (DLBCL) is themost common type
of B-cell non-Hodgkin lymphoma. Several genetic aberrations
are known to underlie DLBCL development and progression.
Recently, we identified that Cd37-knockout mice spontaneously
develop B-cell lymphoma.1 Moreover, CD37 protein expression
has been reported to be an independent prognostic factor for
patient outcome in R-CHOP (rituximab, cyclophosphamide,
doxorubicin, vincristine, prednisone)-treated DLBCL patients.2
CD37 (Tspan-26), a member of the tetraspanin superfamily, is
highly expressed on mature B lymphocytes3 and is currently
studied as novel target for chimeric antigen receptor (CAR)-T cell
therapy4 and antibody-based therapies for patients with relapsed/
refractory non-Hodgkin lymphoma.5,6 Tetraspanins control the
spatial distribution of membrane proteins through specific inter-
actions with (immune-)receptors and signaling molecules, thereby
facilitating intracellular signaling pathways.7,8 Tetraspanins are
associated with different malignancies,9 but the role of altered
tetraspanin function in DLBCL pathogenesis is unclear.
This study evaluated the mutational status of the human CD37
gene in DLBCL patients, particularly in DLBCL at immune-
privileged sites (IP-DLBCL), including primary testis lymphoma
(PTL) and primary central nervous system lymphoma (PCNSL).
With functional analysis, the effect of identified CD37mutations
on CD37 protein expression at the cell membrane was studied.
Study design
Cases
The study was conducted with 137 archived primary DLBCL
samples, including 44 IP-DLBCL. The discovery cohort included
31 DLBCL samples and 106DLBCL samples were analyzed in the
validation cohort. Samples were collected from multiple Dutch
university hospitals (supplemental Table 1, available on the Blood
Web site).
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Mutation analysis
CD37 mutation analysis of the discovery cohort was performed
by amplicon-based sequencing with Ion Torrent and Sanger
sequencing. For the validation cohort, single-molecule molec-
ular inversion probe mutation analysis and sequencing with Ion
Torrent included the CD37 gene and hotspot loci of CARD11,
CD79A, CD79B, and MYD88.
Functional analysis of mutant CD37
The CD37-Gly88Asp-green fluorescent protein (GFP) and CD37-
Gly65Glu-GFPmutant constructs were generated by introducing
point mutations c.263G.A or c.194G.A in hCD37-wild-type
(WT)-GFP1 using site-directed mutagenesis. Human BJAB and
OCI-Ly8 lymphoma B cells were transfected with the AMAXA
Nucleofector or the Neon transfection system and analyzed for
CD37 protein expression and subcellular localization using western
blot and confocal fluorescence microscopy.
Additional experimental details are provided in supplemental
Materials and methods.
Results and discussion
In a discovery cohort of 31 DLBCL cases, including 5 PTL cases,
CD37mutations were analyzed. CD37mutations were identified
in 2 PTL cases, 1 harboring a missense mutation (c.263G.A
(p.Gly88Asp)) and the other a splice-site mutation (c.343-1G.C),
but none were identified in the non-IP-DLBCL samples (n 5 26).
To confirm this finding, a validation cohort consisting of 39 IP-
DLBCL cases (18 PTL and 21 PCNSL) and 67 non-IP-DLBCL cases
was analyzed for CD37 mutations along with CARD11, CD79A,
CD79B, and MYD88 hotspot mutations (Figure 1; supple-
mental Table 2). In this analysis, we also included the 5 PTL
cases from the discovery cohort. Besides confirmation of the 2
initially identified CD37 mutations, we uncovered 12 additional
mutations (variant allele frequency 5.7% to 49%; Figure 1B-C).
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Figure 1. High frequency ofmutatedCD37 in IP-DLBCL. (A) Frequency ofCD37mutations in non-IP-DLBCL vs IP-DLBCL. The total number of lymphoma cases for each group
is indicated. Numbers in the CD37 mutation row indicate the number of lymphoma cases carrying $1 CD37mutation. P values were obtained using the Fisher’s exact test. (B)
OncoPrint (left) and Venn diagram (right) show the frequencies of CD37, CARD11, CD79A, CD79B, andMYD88mutations in all IP-DLBCL cases studied (23 PTL and 21 PCSNL).
Columns show individual tumors. Asterisk indicates samples from the same patient containing the CD37 germline mutation. Genetic details per mutation can be found in
supplemental Table 2. Green, missense mutation; black, splice-site mutation; magenta, deletion; gray, no mutation. (C) Schematic representation of mutations detected in
the CD37 gene. Dark gray boxes represent the coding sequence of CD37, light gray boxes are the noncoding sequence before exon 1 (begin) and after exon 8 (end), and
black lines represent introns. Asterisk indicates the CD37 germline mutation.
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Figure 2. Mutations in CD37 cause aberrant CD37 glycosylation and localization.Western blot analysis of CD37 protein expression in BJAB lymphoma B cells transfected
with CD37-WT-GFP, CD37-Gly88Asp-GFP (A), or CD37-Gly65Glu-GFP (B). Blots were probed with a-GFP to detect CD37-GFP expression (50-75 kDa; upper blot). a-Tubulin was
used as a loading control (lower blot). Protein expression level of CD37-mutant-GFP was normalized to CD37-WT-GFP for each experiment (n 5 3). ns, not significant (P 5 .73
[left], P5 .96 [right]), paired t test. (C) Confocal microscopy images of BJAB cells expressing CD37-WT-GFP and CD37-Gly88Asp-GFP or CD37-Gly65Glu-GFP (green) costained
for MHC-I (red) to identify the plasma membrane. Overview images (top) and single-cell images (bottom left) show representative cells of 3 independent experiments for
both CD37-WT-GFP and CD37-mutant-GFP. Scale bar, 10 mm. Ratio between membrane and cytoplasmic GFP expression was quantified from 10 representative cells of
3 independent experiments. *P 5 .023 (left), P 5 .011 (right), paired t test. All data represent mean 6 standard error of the mean.
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Intriguingly, all CD37 mutations were exclusively present in IP-
DLBCL cases (n5 10/44, 23%); and none were present in the non-
IP-DLBCL cases (n50/93; Fisher’s exact test,P5 .0001; Figure 1A).
Mutation rates of frequently affected genes CARD11 (5%), CD79A
(5%), CD79B (50%), and MYD88 (64%) in our cohort (Figure 1B;
supplemental Table 2) were in line with other DLBCL studies.10-13
Whole-genome and exome sequencing studies of DLBCL report
low mutation frequencies of CD37, ranging from no mutations
to 8%.11,14-17
The CD37 mutations identified in the validation cohort were
detected in 8 IP-DLBCL cases and included 9 missense muta-
tions (c.109C.T (p.Leu37Phe), c.194G.A (p.Gly65Glu) [twice],
c.279G.A (p.Met93Ile), c.279G.T (p.Met93Ile), c.460G.A,
(p.Gly154Ser), c.656T.G (p.Val219Gly), c.337G.A (p.Ala113Thr),
and c.827G.A (p.Arg276Gln)), 1 in-frame deletion (c.364_399del
(p.Val122_Asn133del)), and 2 splice-site mutations (c.266_267110del,
c.268-2A.C) (Figure 1C; pathogenicity scores are listed in sup-
plemental Table 2).Within 1 patient, missensemutation c.194G.A
(p.Gly65Glu) was detected in 2 primary lymphoma specimens as
well as healthy control tissue, but not described as a single-
nucleotide polymorphism, indicating the presence of a CD37
germline mutation. To the best of our knowledge, this is the first
reported CD37 germline mutation in humans.
To determine the effect of splice-site mutation c.343-1G.C,
complementary DNA of this DLBCL sample was sequenced,
which revealed an 11-bp deletion (supplemental Figure 1). This
resulted in a frameshift in the CD37mRNA sequence, leading to
a completely altered protein after transmembrane domain 3.
Based on previous studies on tetraspanin CD81 in B cells,18 this
mutation is predicted to result in a nonfunctional CD37 protein,
since the essential extracellular domain 2 is truncated.19 Next,
theCD37missense mutations and in-frame deletion were mapped
onto the reported crystal structure of tetraspanin CD8120 (sup-
plemental Figure 2). Deletion c.364_399del (p.Val122_Asn133del)
disrupts an important structural element of extracellular domain 2,
namely the A helix, and is therefore also predicted to result in
a nonfunctional CD37 protein.19
To further assess whether the observed missense mutations
resulted inCD37 loss of function, we introduced2of the identified
CD37 mutations, c.263G.A (p.Gly88Asp) and c.194G.A
(p.Gly65Glu), in human lymphoma B cells using aGFP expression
vector. WT CD37 protein appeared as 50- to 75-kDa bands on
western blot (Figure 2A-B; supplemental Figure 3A) due to
heavy glycosylation. Protein isoforms with the highest glycosylation
state (670 kDa) were less pronounced in lymphoma B cells
expressing mutant CD37-Gly88Asp-GFP (Figure 2A), and
CD37-Gly65Glu-GFP showed a lower-molecular-weight band
on western blot indicating a glycosylation defect (Figure 2B).
Total CD37-GFP protein levels of both mutants were similar to
CD37-WT-GFP (Figure 2A-B).
Next, the subcellular localization of the CD37 mutants was de-
termined using confocalmicroscopy. LymphomaB cells expressing
the CD37-GFP mutants had significantly lower cell membrane
expression andmore retention of intracellular CD37 protein than
cells expressing CD37-WT-GFP (Figure 2C; supplemental Figure
3B). Moreover, CD37-Gly88Asp had a dominant-negative effect
on the membrane expression of CD37-WT protein (supplemental
Figure 4). These data indicate that these missense mutations
result in defective glycosylation and trafficking of CD37 in
human lymphoma B cells, which corresponds to the reported
role of glycosylation as a sorting signal for protein transport to
the plasma membrane.21 Moreover, modification of cell-surface
proteins by defective glycosylation frequently contributes to
cancer development by enhancing invasive growth and tumor
cell migration.22
We previously showed that loss of CD37 results in increased
interleukin-6 signaling and STAT3 activation,1 which are both
known to be involved in the pathogenesis of hematological
malignancies.23 MYD88 mutations also stimulate cell survival by
promoting JAK/STAT3 signaling and interleukin-6 secretion,
suggesting a similar phenotype.24 As proposed for MYD88
and CD79B mutations in IP-DLBCL,12 mutations in CD37 could
therefore provide a survival advantage in the otherwise stimulus-
poor environment of immune-privileged sites.
Seven out of 9 evaluable cases with a CD37 mutation did not
express CD37 protein (supplemental Figure 5 and supplemental
Table 1). Since immunohistochemistry does not distinguish
between cell-surface and cytosolic expression, the importance
of CD37 in DLBCL biology1,2 is likely underestimated. Moreover,
the recent identification of loss of CD19 expression as a mecha-
nism underlying disease relapse upon CD19 CAR-T cell therapy25
emphasizes the need to investigate CD37 surface expression in
hematologic malignancies prior to the use of novel CD37 CAR-T
cell therapies.
In conclusion, inactivating CD37mutations occur predominantly
in IP-DLBCL and lead to aberrant CD37 cell-surface expression.
This study provides novel molecular insight into DLBCL at
immune-privileged sites and indicates that CD37-based thera-
pies are more likely to be beneficial for DLBCL patients that
harbor no CD37 mutations.
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